{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:19:35Z","timestamp":1790720375845,"version":"4.1.0"},"reference-count":29,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"unspecified","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018720","name":"Advanced Accelerator Applications","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100018720","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Suitability for peptide receptor radionuclide therapy (PRRT) for neuroendocrine neoplasia (NENs) depends on presence of somatostatin receptor-2 (SSTR2) determined by [68Ga]Ga-DOTA-peptide-positron emission tomography (PET). Some patients have low or no uptake on [68Ga]Ga-DOTA-peptide-PET, precluding PRRT. The upstream promoter region of SSRT2 is methylated, with percentage of methylation correlating with SSTR2 expression. Demethylating agents increase uptake on PET imaging in vivo such that tumours previously negative on PET become positive, correlating with a dose dependent increase in tumorous SSTR2 expression. LANTana will determine whether treatment with the demethylating agent, ASTX727, results in re-expression of SSTR2 using [68Ga]Ga-DOTA-peptide-PET to image epigenetic modification of the SSTR2 locus, allowing subsequent PRRT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>27 participants with a histological diagnosis of NEN (Ki67<jats:underline>&lt;<\/jats:underline>55%) with no or low uptake on baseline [68Ga]Ga-DOTA-TATE-PET\/CT will be recruited. Patients will receive 5\u2009days of ASTX727 (fixed dose 35\u2009mg decitabine+100\u2009mg cedazuridine). [68Ga]Ga-DOTA-peptide-PET\/CT will be repeated day 8\u00b12; where there is significant uptake greater than liver in most lesions, PRRT will be administered. Primary objective is to determine re-expression of SSTR2 on PET imaging. Tolerability, progression-free survival, overall response and quality of life will be assessed. Methylation in peripheral blood mononuclear cells and tumorous methylation will be evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>LANTana has ethical approval from Leeds West Research Ethics Committee (REC Reference: 21\/YH\/0247).<\/jats:p><jats:p>Sponsored by Imperial College London and funded by Advanced Accelerator Applications pharmaceuticals. Results will be presented at conferences and submitted to peer-reviewed journals for publication and will be available on ClinicalTrials.gov.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration numbers<\/jats:title><jats:p>EUDRACT number: 2020-003800-15,<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05178693\">NCT05178693<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2023-075221","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T03:21:17Z","timestamp":1698204077000},"page":"e075221","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Study protocol of LANTana: a phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]Lu-DOTA-TATE in patients with metastatic neuroendocrine tumours, UK"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct05178693","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ravindhi","family":"Murphy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurvin","family":"Chander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sairah R","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitesh","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Barwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Aboagye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2441-549X","authenticated-orcid":false,"given":"Rohini","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,10,24]]},"reference":[{"key":"2023102420201589000_13.10.e075221.1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with Neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"2023102420201589000_13.10.e075221.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70410-2"},{"key":"2023102420201589000_13.10.e075221.3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds276"},{"key":"2023102420201589000_13.10.e075221.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.03.304"},{"key":"2023102420201589000_13.10.e075221.5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28721"},{"key":"2023102420201589000_13.10.e075221.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2007.01.004"},{"key":"2023102420201589000_13.10.e075221.7","doi-asserted-by":"publisher","DOI":"10.1385\/EP:15:4:275"},{"key":"2023102420201589000_13.10.e075221.8","doi-asserted-by":"publisher","DOI":"10.1159\/000443167"},{"key":"2023102420201589000_13.10.e075221.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.8510"},{"key":"2023102420201589000_13.10.e075221.10","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic Enteropancreatic Neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"2023102420201589000_13.10.e075221.11","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa1607427","article-title":"177Lu-Dotatate for Midgut Neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"2023102420201589000_13.10.e075221.12","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1200\/JCO.2018.78.5865","article-title":"Health-related quality of life in patients with progressive Midgut Neuroendocrine tumors treated with (177)Lu-Dotatate in the phase III NETTER-1 trial","volume":"36","author":"Strosberg","year":"2018","journal-title":"J Clin Oncol"},{"key":"2023102420201589000_13.10.e075221.13","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.18.19881"},{"key":"2023102420201589000_13.10.e075221.14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.230607"},{"key":"2023102420201589000_13.10.e075221.15","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.2967\/jnumed.118.223016","article-title":"111 In-Pentetreotide scintigraphy versus (68)Ga-DOTATATE PET: impact on Krenning scores and effect of tumor burden","volume":"60","author":"Hope","year":"2019","journal-title":"J Nucl Med"},{"key":"2023102420201589000_13.10.e075221.16","doi-asserted-by":"publisher","DOI":"10.1148\/rg.352140164"},{"key":"2023102420201589000_13.10.e075221.17","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.7150\/thno.18068","article-title":"Dual Somatostatin receptor\/FDG PET\/CT imaging in metastatic Neuroendocrine tumours: proposal for a novel grading scheme with Prognostic significance","volume":"7","author":"Chan","year":"2017","journal-title":"Theranostics"},{"key":"2023102420201589000_13.10.e075221.18","doi-asserted-by":"publisher","DOI":"10.1210\/en.2007-1525"},{"key":"2023102420201589000_13.10.e075221.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.165092"},{"key":"2023102420201589000_13.10.e075221.20","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9462"},{"key":"2023102420201589000_13.10.e075221.21","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejca.2022.09.009","article-title":"Epigenetic potentiation of Somatostatin-2 by Guadecitabine in Neuroendocrine Neoplasias as a novel method to allow delivery of peptide receptor radiotherapy","volume":"176","author":"Evans","year":"2022","journal-title":"Eur J Cancer"},{"key":"2023102420201589000_13.10.e075221.22","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.169532"},{"key":"2023102420201589000_13.10.e075221.23","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(19)30030-4","article-title":"An oral fixed-dose combination of Decitabine and Cedazuridine in myelodysplastic syndromes: a Multicentre, open-label, dose-escalation, phase 1 study","volume":"6","author":"Savona","year":"2019","journal-title":"Lancet Haematol"},{"key":"2023102420201589000_13.10.e075221.24","doi-asserted-by":"publisher","DOI":"10.1053\/snuc.2002.31022"},{"key":"2023102420201589000_13.10.e075221.25","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.annonc.2021.01.003","article-title":"Lung and Thymic Carcinoids: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2606","volume":"32","author":"Baudin","year":"2021","journal-title":"Ann Oncol"},{"key":"2023102420201589000_13.10.e075221.26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv041"},{"key":"2023102420201589000_13.10.e075221.27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264860"},{"key":"2023102420201589000_13.10.e075221.28","unstructured":"Fayers PM , Aaronson NK , Bjordal K . The EORTC QLQ-C30 scoring manual. In: Cancer. Brussels: European Organisation for Research and Treatment of Cancer, 2001."},{"key":"2023102420201589000_13.10.e075221.29","doi-asserted-by":"crossref","unstructured":"Chan A-W , Tetzlaff JM , G\u00f8tzsche PC , et al . SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586. doi:10.1136\/bmj.e7586","DOI":"10.1136\/bmj.e7586"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-075221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T03:21:29Z","timestamp":1698204089000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-075221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10,24]]},"published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1136\/bmjopen-2023-075221"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-075221","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]}}}